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a b s t r a c t
Granulocyte-colony stimulating factor (G-CSF) is a therapeutic approach to increase peripheral neutrophil
counts after anti-tumor therapies. Pain is the major side effect of G-CSF. Intraplantar administration of G-CSF in
mice induces mechanical hyperalgesia. However, the peripheral mechanisms involved in this effect were not
elucidated. Therefore, the participation of pronociceptive cytokines tumor necrosis factor (TNF) alpha (TNFα),
interleukin (IL)-1 beta (IL-1β) and antinociceptive cytokine IL-10 in G-CSF-induced mechanical hyperalgesia in
mice was investigated. G-CSF-induced mechanical hyperalgesia was inhibited by systemic and local treatment
with etanercept and IL-1 receptor antagonist (IL-1ra) or TNF receptor 1 (TNFR1) deﬁciency and increased in IL-
10 deﬁcient mice. In agreement, G-CSF injection induced signiﬁcant TNFα, IL-1β and IL-10 production in paw
tissue. G-CSF-induced hyperalgesia was dose-dependently inhibited by thalidomide (5–45mg/kg) and
pentoxifylline (0.5–13.5 mg/kg), and treatment with these drugs inhibited G-CSF-induced TNFα, IL-1β and
IL-10 production. The combined treatment with pentoxifylline or thalidomide with morphine, at doses that
are ineffective as single treatment, diminished G-CSF-induced hyperalgesia through inhibiting cytokine
production. Indomethacin also reduces G-CSF hyperalgesia alone or combined with pentoxifylline or
thalidomide. Thus, G-CSF-induced hyperalgesia might be mediate by peripheral production of pronoci-
ceptive cytokines TNFα and IL-1β and down-regulated by IL-10. Systemic IL-1ra reduced G-CSF-induced
increase of peripheral neutrophil counts. However, local treatment with morphine, IL-1ra or etanercept,
and systemic treatment with indomethacin, etanercept, thalidomide and pentoxifylline did not alter
G-CSF-induced mobilization of neutrophils. Therefore, this study advances in the understanding of G-CSF-
induced hyperalgesia and suggests therapeutic approaches for its control.
& 2015 Elsevier B.V. All rights reserved.
1. Introduction
Commercial forms of granulocyte-colony stimulatory factor (G-CSF)
such as ﬁlgrastim and biosimilars are clinically used to induce
granulopoiesis in conditions such as myelosuppressive chemotherapy,
acute myeloid leukemia and severe chronic neutropenia (Battiwalla
and McCarthy, 2009; Dale et al., 1993; Filgrastim Package Insert, 2010;
Santjohanser et al., 2013). The main side effect of G-CSF therapy is pain
as reported by healthy volunteers and cancer patients (Battiwalla and
McCarthy, 2009; Filgrastim Package Insert, 2010).
Corroborating the hyperalgesic role of G-CSF, nociceptive neurons
express G-CSF receptor and targeting this receptor inhibits pancreatic
carcinoma-induced hyperalgesia (Schweizerhof et al., 2009).
Carrageenan-induced facial inﬂammatory pain was also related to
increased G-CSF mRNA expression (Poh et al., 2011). The intraplantar
(i.pl.) administration of G-CSF induces mechanical hyperalgesia by a
mechanism dependent on spinal activation of mitogen activated
protein (MAP) kinases and phosphatidilinositil 3-kinase (PI3K)
(Carvalho et al., 2011) and G-CSF activates these kinases in cancer
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pain (Schweizerhof et al., 2009). Cytokines such as tumor necrosis
factor alpha (TNFα) and interleukin (IL)-1 beta (IL-1β) activate these
kinases in models of inﬂammatory and neuropathic pain (Obata et al.,
2004; Pezet et al., 2008; Svensson et al., 2003; Xu et al., 2007). The
hyperalgesia induced by peripheral administration of TNFα and IL-1β
depends on prostaglandin production (Verri et al., 2006). On the other
hand, IL-10 is known by its anti-hyperalgesic effects attributed to
inhibition of TNFα and IL-1β production and action (Poole et al., 1995;
Verri et al., 2006). IL-10 inhibits carrageenan-, TNFα- and IL-1β-
induced mechanical hyperalgesia in rats (Verri et al., 2006). In other
systems, G-CSF induces TNFα, IL-1β and IL-10 production (Bien et al.,
2013; Schmidt et al., 1999). However, the role of TNFα, IL-1β and IL-10
in G-CSF-induced mechanical hyperalgesia is unknown.
Biological therapies targeting cytokines are recognized as impor-
tant anti-inﬂammatory approaches (Murdaca et al., 2014; Niu et al.,
2011; Verri et al., 2006). Additionally, cytokines can be target by non-
biological approaches. For instance, thalidomide and pentoxifylline are
the chosen options for the treatment of several clinical conditions such
as erythema nodosum leprosum and multiple myeloma since they
inhibit TNFα production (Breitkreutz and Anderson, 2008; Majumder
et al., 2012; Putinatti et al., 2014). Thus, they could be considered as
interesting pharmacological approaches for the treatment of cytokine-
dependent inﬂammatory pain diseases in clinical practice.
Opioids are used to treat G-CSF-induced pain in humans
(Filgrastim Package Insert, 2010). G-CSF-induced mechanical hyper-
algesia in mice is also amenable by morphine treatment (Carvalho
et al., 2011). However, prolonged treatment with opioids induces
dependence because of opioid receptors desensitization leading to
increasing doses of morphine. The side effects of morphine include
nausea, constipation, somnolence/sedation, and respiratory failure,
which increase with the dose increment (Devulder et al., 2009).
Interestingly, synergy of thalidomide and pentoxifylline with mor-
phine has been reported and could account to reduce the dose of
morphine (Lee et al., 2013; Lu et al., 2004; Mika et al., 2009).
Taking into account the above evidence, the role of TNFα, IL-1β
and IL-10 in G-CSF-induced mechanical hyperalgesia was evalu-
ated using biological therapies, knockout mice, thalidomide, pen-
toxifylline and indomethacin.
2. Materials and methods
2.1. Animals
The experiments were performed on male C57BL/6 background
(wild type; WT), TNF receptor 1 (TNFR1) deﬁcient ( /) paired with
the respective littermate (C57BL/6 background) and IL-10 / paired
with the respective littermate (C57BL/6 background) mice (20–25 g,
from University of Sao Paulo, Ribeirao Preto Medical School), which
were housed in standard clear plastic cages with free access to food
and water. All behavioral testing was performed between 9:00 a.m.
and 5:00 p.m. in a temperature-controlled room. Animals' care and
handling procedures were in accordance with the International
Association for Study of Pain (IASP) guidelines, with the EC Directive
86/609/EEC for animal experiments and with the approval of the
Ethics Committee of the Universidade Estadual de Londrina. All
efforts were made to minimize the number of animals used and
their suffering.
2.2. Drugs
Drugs were obtained from the following sources: G-CSF (Granulo-
kines, Filgrastim, recombinant human G-CSF, 100 ng/paw) from Hof-
fmann La-Roche (Basileia, Swiss), indomethacin (0.5–5 mg/kg)
from Prodome (Campinas, SP, Brazil), morphine sulfate (2 and
6 mg/paw) from Cristalia (São Paulo, Brazil), etanercept (10 mg/kg)
from Wyeth Indústria Farmacêutica Ltda (São Paulo, Brazil), IL-1ra
(30 mg/kg) from NIBSC (National Institute of Biological Standards ;and
Control, UK), thalidomide (α-N-phthalimodoglutarimide, 5–45mg/kg)
from FUNED (Fundação Ezequiel Dias – Belo Horizonte, Brazil),
pentoxifylline (methylxanthine derivative, 0.5–13.5 mg/kg) from
Sanoﬁ-Aventis Farmacêutica Ltda (Suzano, Brazil). G-CSF, morphine
sulfate, etanercept and IL-1 receptor antagonist (IL-1ra) were dissolved
in saline, thalidomide and pentoxifylline were dissolved in dimethyl
sulfoxide (DMSO) 2% in saline, and indomethacin was dissolved in
Tris/HCl (2-amino-2-hydroxymethylpropan-1,3-diol/hydrochloric acid)
buffer, pH 8.0.
2.3. Experimental protocols
TNFR1 / , IL-10 / and the respective WT (C57BL/6 background)
mice received intraplantar (i.pl.) injection of G-CSF (100 ng/paw) and
mechanical hyperalgesia was evaluated after 1–7 h. Regarding the
effect of pharmacological treatments over mechanical hyperalgesia,
C57BL/6 mice were treated with etanercept (10 mg/kg, intraperitoneal
[i.p.], 48 and 1 h or 1–100 mg/paw, 1 h), IL-1ra (30 mg/kg, i.p., 30 min
or 30–300 pg/paw, 30 min), thalidomide (5–45 mg/kg, i.p., 30 min) or
pentoxifylline (0.5–13.5 mg/kg, i.p., 30 min) before i.pl. administration
of G-CSF (100 ng/paw) and mechanical hyperalgesia was evaluated
after 1–7 h. Cytokine (TNFα, IL-1β and IL-10) levels were determined
2 and 4 h after G-CSF injection (100 ng/paw) or at 2 h after G-CSF
injection in mice previously treated with thalidomide (45 mg/kg, i.p.,
30 min) or pentoxifylline (13.5 mg/kg, i.p., 30 min). In other settings,
mice were treated with morphine (2 mg/25 ml, 1 or 4 h after G-CSF
stimulus), thalidomide (5 mg/kg, 30 min before), pentoxifylline
(0.5 mg/kg, 30 min before), morphine plus thalidomide andmorphine
plus pentoxifylline, and received G-CSF (100 ng/paw) followed by
evaluation of mechanical hyperalgesia at 5 h (peak of hyperalgesia)
and cytokine levels at 2 h (peak of cytokine production). The effect of
indomethacin (0.5–5mg/kg, 40 min before G-CSF), and indomethacin
(0.5 mg/kg, 40 min before G-CSF) plus thalidomide (5 mg/kg, 30 min
before G-CSF) or pentoxifylline (0.5 mg/kg, 30 min before G-CSF)
treatments over G-CSF-induced mechanical hyperalgesia was evalu-
ated after 1–7 h. In the last set of experiments, mice were treated
with vehicles (saline i.pl., saline i.p., DMSO 2% in saline i.p. and/or
Tris/HCl buffer i.p.), IL-1ra (100 pg/paw or 30 mg/kg i.p.), etanercept
(100 mg/paw or 10 mg/kg, i.p.), morphine (6 mg/paw), thalidomide
(45 mg/kg, i.p.), pentoxifylline (13.5 mg/kg, i.p.) or indomethacin
(5 mg/kg, i.p.) at time points described above before G-CSF (100
ng/paw) stimulus. 24 h after G-CSF stimulus blood samples were
collected for total and differential leukocyte counts. The doses
described above were based on previous studies and standardization
in our laboratory (Borghi et al., 2014a, 2014b; Carvalho et al., 2011;
Calil et al., 2014). Saline (25 ml/paw) was used as negative control of
G-CSF injection. It is noteworthy to mention that experimenters for
behavioral tests were blind to treatment condition.
2.4. Electronic pressure-meter test for mice
Mechanical hyperalgesia was tested in mice as previously reported
(Cunha et al., 2004). Brieﬂy, in a quiet room, mice were placed in
acrylic cages (121017 cm3) with wire grid ﬂoors, 15–30 min
before the start of testing. The test consisted of evoking a hindpaw
ﬂexion reﬂex with a hand-held force transducer (electronic von Frey
anesthesiometer; Insight, Ribeirão Preto, SP, Brazil) adapted with a
0.5 mm2 contact area polypropylene tip. The investigator was trained
to apply the tip perpendicularly to the central area of the hind-paw
with a gradual increase in pressure. The end point was characterized
by the removal of the paw followed by clear ﬂinching movements.
After the paw withdrawal, the intensity of the pressure was recorded
automatically. The value for the response was an average of three
measurements. The animals were tested before and after treatment.
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The results are expressed by delta (Δ) withdrawal threshold (in g)
calculated by subtracting the zero-timemeanmeasurements from the
mean measurements (indicated time points) after stimulus. The basal
mechanical withdrawal threshold was 9.570.1 g (mean7S.E.M. of
67 groups, 6 mice per group) before injection of stimulus or vehicle.
There was no difference of basal mechanical withdrawal thresholds
between groups in the same experiment. Basal values of mechanical
thresholds are shown in Supplementary material.
2.5. TNFα, IL-1β and IL-10 levels determination
Mice received intraplantar injection of G-CSF (100 ng) and
2 and 4 h after samples of paw tissue were collected. In another
set of experiments, mice were treated intraperitoneally with
vehicle (DMSO 2% in saline), thalidomide (5–45 mg/kg i.p.) or
pentoxifylline (0.5–13.5 mg/kg i.p.) 30 min before G-CSF stimulus.
In the last set of experiments dosing cytokine levels, mice were
treated with vehicle (saline i.pl., saline i.p., DMSO 2% in saline i.p.
and/or Tris/HCl buffer i.p.), morphine (2 mg/paw, 1 h after G-CSF
stimulus), thalidomide (5 mg/kg, i.p., 30 min before G-CSF), pen-
toxifylline (0.5 mg/kg, i.p., 30 min before G-CSF), morphine plus
thalidomide and morphine plus pentoxifylline and received intra-
plantar injection of G-CSF (100 ng/paw) followed by paw tissue
sample collection after 2 h (peak of cytokine production). TNFα,
IL-1β and IL-10 levels were determined as described previously
(Verri et al., 2010) by enzyme-linked immunosorbent assay (ELISA)
according to manufacturer's instructions (eBioscience). The results
were expressed as picograms (pg) of cytokine per 100 mg of tissue.
2.6. Determination of leukocytes in peripheral blood
Mice were treated with vehicles (saline i.pl., saline i.p., DMSO 2%
in saline i.p. and/or Tris/HCl buffer i.p.), IL-1ra (100 pg/paw, 30 min
before G-CSF or 30 mg/kg, i.p. 30 min before G-CSF), etanercept
(100 mg/paw, 1 h before G-CSF or 10 mg/kg, i.p., 48 and 1 h before
G-CSF), morphine (6 mg/paw, 4 h after G-CSF), thalidomide (45 mg/
kg, i.p., 30 min before G-CSF), pentoxifylline (13.5 mg/kg i.p. 30 min
before G-CSF) and indomethacin (5 mg/kg, i.p., 40 min before
G-CSF) and received i.pl. injection G-CSF (100 ng/paw). 24 h after
the administration of G-CSF, samples of blood were collected to
evaluate total and differential cell counts. Total cell counts were
performed in Neubauer chamber usign Turk solution, and differ-
ential cells counts (100 cells per slide) were performed in blood
slides stained with panoptic kit (Laborclin Produtos para Laboratór-
ios Ltda., Pinhais, PR, Brazil) under light microscope (Zeiss, Wetzlar,
Germany). Results were expressed as total leukocytes, mononuclear
cells and neutrophils (cells105/ml of blood).
Fig. 1. TNFα/TNFR1, IL-1β and IL-10 modulate G-CSF-induced mechanical hyperalgesia in mice. G-CSF (100 ng/paw) was injected in mice treated with etanercept (10 mg/kg,
i.p., 48 and 1 h before) (Panel A), TNFR1/ mice (Panel B), IL-1ra treated mice (30 mg/kg, i.p., 30 min before) (Panel C) and IL-10/ mice (Panel D). Intraplantar (i.pl.)
injection of saline (25 ml)þ i.p. treatments with saline, etanercept and IL-1ra or TNFR1 / and IL-10/ mice were used as negative controls of G-CSFþtreatments/genetic
deﬁciency. Mechanical hyperalgesia was evaluated after 1–7 h. Results are presented as mean7S.E.M. of 6 mice per group per experiment, and are representative of
2 separated experiments. *Po0.05 compared to saline i.pl.þvehicle i.p. and vehicle i.pl.þtreatment i.p./deﬁcient mice control groups; #Po0.05 compared to the
G-CSFþvehicle i.p./littermate WT groups (One-way ANOVA followed by Tukey's t-test).
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2.7. Statistical analysis
Results are presented as mean7S.E.M. of measurements per-
formed on 6 mice per group per experiment. The experiments
were performed twice. Two-way analysis of variance (ANOVA) was
used to compare the groups and doses at all times (curves) when
the hyperalgesic responses were measured at different times after
the stimulus injection. The analyzed factors were treatments, time
and time versus treatment interaction. When there was a signiﬁ-
cant time versus treatment interaction, one-way ANOVA followed
by Tukey's t-test was performed for each time. On the other hand,
when the hyperalgesic responses were measured once after the
stimulus injection, the differences between responses were eval-
uated by one-way ANOVA followed by Tukey's t-test. Statistical
differences were considered to be signiﬁcant at Po0.05.
3. Results
3.1. G-CSF-induced mechanical hyperalgesia depends on
hyperalgesic TNFα/TNFR1 and IL-1β signaling pathway and is
down-regulated by IL-10 in mice
Firstly, the effect of targeting TNFα, IL-1β and IL-10 action/
production in the G-CSF-induced mechanical hyperalgesia was eval-
uated (Fig. 1). To achieve this aim G-CSF (100 ng/paw) was injected in
mice treated with etanercept (10 mg/kg, i.p., 48 and 1 h before)
(Fig. 1A), TNFR1 / mice (Fig. 1B), IL-1ra treated mice (30 mg/kg, i.
p., 30 min before) (Fig. 1C) and IL-10 / mice (Fig. 1D). Intraplantar (i.
pl.) injection of saline (25 ml) plus i.p. treatments with saline,
etanercept and IL-1ra or TNFR1 / and IL-10 / mice were used
as negative controls of G-CSF plus treatments/genetic deﬁciency.
Mechanical hyperalgesia was evaluated after 1–7 h after G-CSF
injection (Fig. 1). G-CSF induced signiﬁcant mechanical hyperalgesia
1–7 h after administration compared to the control groups (G-CSF
vehicle, salineþ i.p. treatments or G-CSF vehicle injection in deﬁcient
mice), reaching its peak at the 5th h (Fig. 1). The treatment with
etanercept (Fig. 1A) or TNFR1 deﬁciency (Fig. 1B) inhibited G-CSF-
induced mechanical hyperalgesia. The anti-hyperalgesic effect of
etanercept (Fig. 1A) and TNFR1 deﬁciency (Fig. 1B) was signiﬁcant
between 1 and 7 h after G-CSF administration. IL-1ra (Fig. 1C) treat-
ment also inhibited G-CSF-induced mechanical hyperalgesia between
1 and 7 h. On the other hand, G-CSF-induced mechanical hyperalgesia
was signiﬁcantly higher in IL-10 / mice compared to WT group
between 3 and 7 h, without differences at 1 h (Fig. 1D). These data
demonstrate that TNFα acting on TNFR1 and IL-1β are involved in the
hyperalgesic mechanisms triggered by G-CSF while IL-10 has an anti-
hyperalgesic endogenous role.
3.2. Local treatment with etanercept and IL-1ra reduced
G-CSF-induced mechanical hyperalgesia in mice
Mice received local paw treatment with vehicle (saline), etaner-
cept (1–100 mg, i.pl.) 1 h before, or IL-1ra (30–300 pg, i.pl.) 30 min
before ipsilateral stimulus with G-CSF (Fig. 2). Mice that received i.pl.
injection of saline, etanercept (100 mg/paw) or IL-1ra (100 pg/paw)
without G-CSF stimulus were used as control groups. G-CSF-induced
mechanical hyperalgesia was dose-dependent inhibited by local paw
treatment with etanercept (Fig. 2A) and IL-1ra (Fig. 2B). The doses
of 1 and 10 mg/paw of etanercept did not affect G-CSF-induced
hyperalgesia while 100 mg/paw of etanercept signiﬁcantly inhibited
G-CSF-induced mechanical hyperalgesia between 1 and 7 h (Fig. 2A).
The dose of 30 pg/paw of IL-1ra did not affect G-CSF-induced
mechanical hyperalgesia and the doses of 100 and 300 pg/paw of
IL-1ra inhibited G-CSF-induced mechanical hyperalgesia with similar
proﬁle between 1 and 7 h (Fig. 2B). Thus, the doses of 100 mg/paw of
etanercept and 100 pg/paw of IL-1ra were chosen for the next set
of experiments. Treatment of contralateral paw with etanercept
(Fig. 2C) and IL-1ra (Fig. 2D) did not affect G-CSF-induced mechanical
hyperalgesia. These data demonstrate the participation of peripheral
TNFα and IL-1β in G-CSF-induced mechanical hyperalgesia.
3.3. G-CSF injection induces the production of TNFα, IL-1β and IL-10
in the mice paw
Mice received i.pl. injection of saline or G-CSF, and TNFα, IL-1β
and IL-10 levels were determined 2 and 4 h after stimulus (Fig. 3).
G-CSF induced signiﬁcant TNFα, IL-1β and IL-10 production in the
paw skin at 2 h (Fig. 3). Only IL-1β production was still at
signiﬁcantly increased levels at 4 h (Fig. 3). Therefore, cytokine
levels were determined at 2 h after G-CSF stimulus in the experi-
ments presented at Figs. 5 and 6. These results indicate that G-CSF
administration induces local production of TNFα, IL-1β and IL-10.
3.4. Thalidomide and pentoxifylline inhibited G-CSF-induced
mechanical hyperalgesia in a dose-dependent manner in mice
Mice were treated with vehicle (DMSO 2% in saline, i.p.), thalido-
mide (5–45mg/kg, i.p.) or pentoxifylline (0.5–13.5 mg/kg, i.p.) 30 min
before i.pl. stimulus with G-CSF and mechanical hyperalgesia was
evaluated 1–7 h after (Fig. 4). Negative control groups received i.pl.
injection of saline combined with i.p. injection of the DMSO 2% in
saline or the higher doses treatments used in the dose–response
curves. The dose of 5 mg/kg of thalidomide inhibited G-CSF-induced
mechanical hyperalgesia at 3 h only (Fig. 4A). The dose of 15 mg/kg
of thalidomide inhibited G-CSF-induced mechanical hyperalgesia
3–7 h after G-CSF injection (Fig. 4A), and the dose of 45 mg/kg of
thalidomide inhibited G-CSF-induced mechanical hyperalgesia
1–7 h with signiﬁcant differences compared to the lower dose of
thalidomide tested (5 mg/kg) at 5 and 7 h (Fig. 4A). The dose of
0.5 mg/kg of pentoxifylline did not affect G-CSF-induced mechanical
hyperalgesia. On the other hand, pentoxifylline at the dose of 1.5 mg/
kg inhibited G-CSF-induced mechanical hyperalgesia at 3 h only
(Fig. 4B), and at the doses of 4.5 and 13.5 mg/kg of pentoxifyl-
line inhibited signiﬁcantly G-CSF-induced mechanical hyperalgesia
between 3 and 7 h with signiﬁcant differences compared to pentox-
ifylline at the dose of 0.5 mg/kg group at 7 h (Fig. 4B). Thus, the doses
of 45 mg/kg of thalidomide and 13.5 mg/kg of pentoxifylline were
chosen for the next set of experiments on cytokine production.
3.5. Thalidomide and pentoxifylline inhibited G-CSF-induced TNFα,
IL-1β and IL-10 production in the paw skin of mice
Mice were treated with thalidomide (45 mg/kg, i.p.) and
pentoxifylline (13.5 mg/kg, i.p.) 30 min before receiving i.pl. injec-
tion of vehicle (saline) or G-CSF and after additional 2 h, samples
of paw skin were collected for TNFα, IL-1β and IL-10 dosage
(Fig. 5). DMSO 2% in saline i.p. was injected in the negative (saline
i.pl.) and positive (G-CSF i.pl.) control groups (vehicle was not
indicated in the ﬁgure). In agreement with the results of Figs. 1–4,
G-CSF increased the levels of these three cytokines and pretreat-
ment with thalidomide and pentoxifylline signiﬁcantly inhibited
G-CSF induced TNFα and IL-1β production (Fig. 5). G-CSF-induced
IL-10 production was diminished only by pentoxifylline (Fig. 5).
3.6. Combined treatment of morphine with thalidomide or
pentoxifylline at doses that are ineffective as single treatment reduces
G-CSF-induced mechanical hyperalgesia through inhibition of TNFα
and IL-1β production
The capability of the combined treatment of the ineffective
doses of morphine with thalidomide or pentoxifylline to induce
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analgesia at the peak (5th h) of G-CSF-induced mechanical hyp-
eralgesia was tested (Fig. 6). Only one time point of evaluation was
selected because the analgesic effect of morphine at this protocol
is limited to 1 h (Carvalho et al., 2011). Mice received the following
single treatments: vehicle (saline, 25 ml/paw and DMSO 2% in
saline, 200 ml, i.p.), morphine (2 mg/25 ml, i.pl., 4 h after in Panel
A and 1 h after in Panels B and C), thalidomide (5 mg/kg, i.p.,
30 min before), pentoxifylline (0.5 mg/kg, i.p., 30 min before), or
co-treatment with morphine and thalidomide or pentoxifylline
(same doses described above) at indicated time points before and
after G-CSF stimulus. G-CSF induced signiﬁcant mechanical hyper-
algesia at 5 h after stimulus compared to the vehicle group
(saline), which was unaffected by single treatment with morphine,
thalidomide and pentoxifylline (Fig. 6A). On the other hand, the
combined treatments of morphine with thalidomide or pentoxifyl-
line that were ineffective as single treatment signiﬁcantly inhib-
ited G-CSF-induced mechanical hyperalgesia (Fig. 6A). In order to
determine whether the analgesic effects of co-treatments with
morphine and thalidomide or pentoxifylline act by inhibiting pro-
inﬂammatory cytokine production, TNFα and IL-1β levels were
evaluated at 2 h (peak of cytokine production, Fig. 3) (Fig. 6B and
C). G-CSF induced signiﬁcant production of TNFα and IL-1β
compared to the vehicle group without alteration under single
treatment with morphine, thalidomide and pentoxifylline. How-
ever, the combined treatments were effective in inhibiting G-CSF-
induced TNFα (Fig. 6B) and IL-1β (Fig. 6C) production, indicating
that the mechanism by which the co-treatments induce analgesia
Fig. 3. G-CSF induces TNFα, IL-1β and IL-10 production in the mice paw skin. Mice
received i.pl. injection of saline (25 ml/paw) or G-CSF (100 ng/paw), and after 2 and
4 h, paw skin samples were collected for measurement of TNFα, IL-1β and IL-10
levels by ELISA. Results are presented as mean7S.E.M. of 6 mice per group per
experiment, and are representative of 2 separated experiments. *Po0.05 compared
to the vehicle group (One-way ANOVA followed by Tukey's t-test).
Fig. 2. Local paw treatment with etanercept and IL-1ra reduced G-CSF-induced mechanical hyperalgesia in mice. Mice were treated with etanercept (1–100 mg, i.pl., 1 h
before) (Panel A) or IL-1ra (30–300 pg, i.pl., 30 min before) (Panel B) and received ipsilateral i.pl. injection of G-CSF (100 ng). Etanercept (100 mg, i.pl., 1 h before) (Panel C) or
IL-1ra (100 pg, i.pl., 30 min before) (Panel D) was also injected in the contralateral paw to G-CSF (100 ng) injected paw. Saline (25 ml/paw) plus i.pl. vehicle, etanercept
(100 mg/paw) or IL-1ra (100 pg/paw) were used as negative control groups of G-CSFþtreatments. Mechanical hyperalgesia was evaluated in paw receiving G-CSF 1–7 h its
injection. Results are presented as mean7S.E.M. of 6 mice per group per experiment, and are representative of 2 separated experiments. *Po0.05 compared to saline i.pl.
plus vehicle i.pl./treatments groups; #Po0.05 compared to the G-CSFþvehicle group (One-way ANOVA followed by Tukey's t-test).
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depends, at least in part, on targeting peripheral pro-inﬂammatory
cytokine production induced by G-CSF stimulus.
3.7. Combined treatment of indomethacin with thalidomide or
pentoxifylline at doses that are ineffective as single treatment reduces
G-CSF-induced mechanical hyperalgesia
Opioids constitute the analgesic choice to control G-CSF-induced
pain. However, non-narcotic analgesics can also be used to control
G-CSF-induced pain in humans (Filgrastim Package Insert, 2010). In
this sense, mice were treated with indomethacin (cyclooxygenase
inhibitor, 0.5–5 mg/kg, i.p.), 40 min before i.pl. injection of vehicle
(saline) or G-CSF and mechanical hyperalgesia was evaluated 1–7 h
after (Fig. 7A). Negative control groups received i.pl. injection of saline
combined with i.p. injection of indomethacin vehicle (Tris/HCl buffer)
or the higher dose of indomethacin tested. The dose of 0.5 mg/kg of
indomethacin did not affect G-CSF-induced mechanical hyperalgesia.
On the other hand, indomethacin at the dose of 5 mg/kg inhibited
G-CSF-induced mechanical hyperalgesia between 3 and 7 h (Fig. 7A).
In the following experiment the possibility of inhibiting G-CSF-
induced mechanical hyperalgesia was tested using the co-treatment
with indomethacin and thalidomide or pentoxifylline at doses that
were ineffective alone. Mice received the same treatments (vehicles,
thalidomide and pentoxifylline at the same doses, times and routes)
applied in the experiment shown at Fig. 6 replacing morphine by
indomethacin (0.5 mg/kg, i.p., 40 min before as single dose) and its
vehicle (Tris/HCl buffer), or indomethacin plus thalidomide or
pentoxifylline (Fig. 7B). G-CSF stimulus induced signiﬁcant mechan-
ical hyperalgesia when compared to the vehicle group, which again
was unaffected by single treatment with indomethacin, thalidomide
and pentoxifylline as single treatments. On the other hand, co-
treatment with indomethacin and thalidomide or pentoxifylline
signiﬁcantly inhibited G-CSF-induced mechanical hyperalgesia from
3 to 7 h (Fig. 7B).
3.8. Effect of analgesic treatments on G-CSF-induced peripheral
blood neutrophil counts
The major therapeutic use of G-CSF is the increase of circulating
neutrophils (Lambertini et al., 2014), and according to the Filgrastim
Package Insert (2010), neutropenia could be reverted in a shorter
period such as 24 h after intravenous (i.v.) or subcutaneous (s.c.)
administration of G-CSF. Corroborating, we observed increase of
neutrophil counts in the peripheral blood of mice 24 h, but not 7 h,
after G-CSF administration (data not shown). Therefore, 24 h after
G-CSF administration was selected to evaluate the effect of analgesic
therapies on G-CSF-induced increase of peripheral blood neutrophil
counts. Mice received i.pl. administration of saline or G-CSF (together
with the vehicles described in Fig. 8) and total leukocytes, mono-
nuclear cells and neutrophils counts were performed (Fig. 8). G-CSF
induced a signiﬁcant increase in total leukocytes (Fig. 8A), mono-
nuclear cells (Fig. 8B) and neutrophils (Fig. 8C) compared to the saline
i.pl. injection. In the neutrophil counts, G-CSF induced the presence of
band cells, which were absent in vehicle treated group (data not
shown). Mice were treated with IL-1ra (i.pl., 100 pg, 30 min before or
i.p., 30 mg/kg, 30 min before), etanercept (i.pl., 100 mg, 1 h before or
i.p., 10 mg/kg, 48 and 1 h before), morphine (i.pl., 6 mg/25 ml, 4 h after,
Carvalho et al., 2011), thalidomide (i.p., 45 mg/kg, 30 min before),
pentoxifylline (i.p., 13,5 mg/kg, 30 min before), indomethacin (i.p.,
Fig. 4. Thalidomide and pentoxifylline inhibited G-CSF-induced mechanical hyperalgesia in a dose-dependent manner. Mice were treated intraperitoneally (i.p.) with vehicle
(DMSO 2% in saline), thalidomide (5–45 mg/kg) (Panel A) or pentoxifylline (0.5–13.5 mg/kg) (Panel B) 30 min before the i.pl. injection of saline (25 ml/paw) or G-CSF (100 ng/
paw). Mechanical hyperalgesia was evaluated after 1–7 h. Results are presented as mean7S.E.M. of 6 mice per group per experiment, and are representative of 2 separated
experiments. *Po0.05 compared to saline i.pl.þvehicle i.p./control treatment i.p. groups; #Po0.05 compared to the G-CSFþvehicle i.p. group; **Po0.05 compared to the
G-CSFþvehicle i.p. group and 5 mg/kg dose of thalidomide (Panel A) and 0.5 mg/kg dose of pentoxifylline (Panel B) groups (One-way ANOVA followed by Tukey's t-test).
Fig. 5. Effect of thalidomide and pentoxifylline on G-CSF-induced TNFα, IL-1β and
IL-10 production in the mice paw skin. Mice were treated intraperitoneally (i.p.)
with vehicle (DMSO 2% in saline, not indicated in the ﬁgure), thalidomide (45 mg/
kg) or pentoxifylline (13.5 mg/kg) 30 min before the i.pl. injection of saline (25 ml/
paw) or G-CSF (100 ng/paw), and after 2 h, paw skin samples were collected for
TNFα, IL-1β and IL-10 levels determination by ELISA. Results are presented as
mean7S.E.M. of 6 mice per group per experiment, and are representative of
2 separated experiments. *Po0.05 compared to saline group; #Po0.05 compared
to the G-CSF group (One-way ANOVA followed by Tukey's t-test).
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5 mg/kg, 40 min before) or the respective vehicles (saline i.p., saline
i.pl., DMSO 2% in saline i.p. or Tris/HCl buffer i.p., respectively) as
indicated and total leukocytes, mononuclear cells and neutrophils
counts were determined (Fig. 8). Vehicles did not change G-CSF-
induced increase of total leukocytes, mononuclear cells and neutro-
phil counts in the peripheral blood (Fig. 8). The i.p. treatment with IL-
1ra signiﬁcantly reduced total leukocytes, mononuclear cells and
neutrophils counts (Fig. 8). IL-1ra, etanercept and morphine at doses
with a local effect, and etanercept, thalidomide, pentoxifylline and
indomethacin at doses with a systemic effect did not affect G-CSF-
induced increase of total leukocytes, mononuclear cells and neutro-
phils counts in peripheral blood.
4. Discussion
G-CSF is mainly used to increase neutrophil counts in peripheral
blood of patients (Lambertini et al., 2014). The most prominent side
Fig. 6. Combined treatment with morphine and thalidomide or pentoxifylline at doses that are ineffective as single treatment inhibited G-CSF-induced mechanical
hyperalgesia and pro-hyperalgesic cytokine production in mice. Mice were treated with vehicle (saline i.pl. 4 h [Panel A] or 1 h [Panels B and C] after or DMSO 2% in saline i.p.
30 min before), morphine (2 mg/paw 4 h after [Panel A], and 1 h after [Panels B and C]), thalidomide (5 mg/kg, i.p., diluted in DMSO 2% in saline, 30 min before), pentoxifylline
(0.5 mg/kg, i.p., diluted in DMSO 2% in saline, 30 min before), or co-treatment with morphine plus thalidomide or morphine plus pentoxifylline, and received i.pl. injection of
G-CSF (100 ng). Mice that received i.pl. injection of saline plus vehicles of morphine (i.pl.) and thalidomide and pentoxifylline (i.p.) were used as negative control group.
Mechanical hyperalgesia (Panel A) was evaluated after 5 h (peak of G-CSF-induced mechanical hyperalgesia), and the production of TNFα (Panel B) and IL-1β (Panel C) was
evaluated after 2 h (peak of cytokine production). Results are presented as mean7S.E.M. of 6 mice per group per experiment, and are representative of 2 separated
experiments. *Po0.05 compared to saline i.pl. group; #Po0.05 compared to the G-CSFþvehicle i.pl.þvehicle i.p. groups (One-way ANOVA followed by Tukey's t-test).
Fig. 7. Indomethacin and combined treatment with indomethacin and thalidomide or pentoxifylline at doses that are ineffective as single treatment inhibited G-CSF-
induced mechanical hyperalgesia. In Panel A, mice were treated intraperitoneally (i.p.) with vehicle (Tris/HCl buffer) or indomethacin (0.5–5 mg/kg) (Panel A) 40 min before
the i.pl. injection of G-CSF (100 ng/paw) (25 ml/paw). In Panel B, mice were treated with vehicle (DMSO 2% in saline and Tris/HCl buffer i.p. 30 and 40 min before,
respectively), indomethacin (5 mg/kg, i.p., 40 min before), thalidomide (5 mg/kg, i.p., 30 min before), pentoxifylline (0.5 mg/kg, i.p., 30 min before), or co-treatment with
indomethacin plus thalidomide or pentoxifylline, and received i.pl. injection of G-CSF or saline (25 ml/paw). Mechanical hyperalgesia was evaluated 1–7 h after G-CSF
injection. Results are presented as mean7S.E.M. of 6 mice per group per experiment, and are representative of 2 separated experiments. *Po0.05 compared to saline i.pl.þ
vehicles/control treatment groups; #Po0.05 compared to the G-CSFþvehicle group; **Po0.05 compared to the G-CSFþvehicle group and G-CSFþ0.5 mg/kg dose of
indomethacin (One-way ANOVA followed by Tukey's t-test).
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effect of G-CSF therapy is pain (Battiwalla and McCarthy, 2009;
Lambertini et al., 2014). We have previously reported that i.pl.
injection of G-CSF is a conceivable model to study G-CSF-induced
pain since it occurs at similar dose of G-CSF used in clinical settings
and is amenable by morphine treatment as observed in clinical
practice (Carvalho et al., 2011). The present study demonstrated that
G-CSF-induced mechanical hyperalgesia depends on TNFα and IL-1β
hyperalgesic effects while IL-10 presents an endogenous role to
control G-CSF-induced mechanical hyperalgesia. In agreement, tar-
geting TNFα and IL-1β production with thalidomide and pentoxifyl-
line reduced G-CSF-induced mechanical hyperalgesia.
TNFα and IL-1β are hyperalgesic cytokines contributing to
inﬂammatory, neuropathic and cancer pain (Cunha et al., 1992,
2003; Ferreira et al., 1988; Liu et al., 2013; Schäfers et al., 2001,
2003; Uçeyler et al., 2009; Zelenka et al., 2005). G-CSF induces TNFα
and IL-1β production in other systems not related to pain (Jiang
et al., 2013; Schmidt et al., 1999). G-CSF-induced mechanical hyper-
algesia was inhibited in TNFR1 / mice, and by systemic and local
treatment with etanercept (a soluble TNF receptor 2) and IL-1ra (IL-1
receptor antagonist), which lined up well with the early G-CSF-
induced production of TNFα and IL-1β in the paw skin. These results
are not completely expected since G-CSF reduced lipopolysaccharide
from gram-negative bacteria (LPS)-induced production of TNFα and
IL-1β in human whole blood by translational silencing of LPS-
induced TNFα mRNA and inhibiting caspase-1 activation and con-
sequent IL-1β release, respectively (Boneberg and Hartung, 2002).
IL-10 is an anti-hyperalgesic cytokine in inﬂammatory, neuro-
pathic and cancer pain (Kim et al., 2011; Milligan et al., 2005; Poole
et al., 1995; Shimizu et al., 2009; Wang et al., 2012). IL-10 / mice
presented enhanced G-CSF-induced mechanical hyperalgesia eviden-
cing the endogenous role of IL-10 as an anti-hyperalgesic cytokine.
The anti-hyperalgesic activity of IL-10 has been attributed to inhibi-
tion of TNFα and IL-1β production (Akdis et al., 2011; Donnelly et al.,
1999; Inoue et al., 2014; Poole et al., 1995) by a mechanism related to
the augmented expression of the suppressor of cytokine signaling-1
and -3 genes resulting in reduced cytokine signaling and immune
response (Akdis et al., 2011; Donnelly et al., 1999).
Cytokine production can be inhibited by drugs such as thali-
domide and pentoxifylline, which induce TNFαmRNA degradation
(Moreira et al., 1993; Ribeiro et al., 2000) and inhibit TNFα mRNA
expression (Verri et al., 2006), respectively. There is also evidence
that thalidomide and pentoxifylline inhibit the production of other
cytokines such as IL-1β, and that pentoxifylline induces IL-10
production (van Furth et al., 1997; Amirshahrokhi and Ghazi-
Khansari, 2012; Amirshahrokhi, 2013; Marcinkiewicz et al., 2000;
Ribeiro et al., 2000; Melo et al., 2008; Vale et al., 2004; Wei et al.,
2009). The analgesic effects of thalidomide and pentoxifylline have
been shown (Cata et al., 2008; Chauhan et al., 2012; Dorazil-
Dudzik et al., 2004; Gu et al., 2010; Ribeiro et al., 2000; Vale et al.,
2004; Wei et al., 2009), and their lower cost compared to
biological therapies associated with known pharmacology, phar-
macokinetics and toxicology suggests their potential therapeutic
applicability (Verri et al., 2006). Herein, thalidomide and pentox-
ifylline inhibited the G-CSF-induced mechanical hyperalgesia and
TNFα and IL-1β production, and pentoxifylline also inhibited IL-10
production indicating that their analgesic effect depends on
inhibition of hyperalgesic cytokine production rather than indu-
cing anti-hyperalgesic IL-10 production.
Morphine combined with thalidomide or pentoxifylline at
ineffectively analgesic doses as single treatment reduced G-CSF-
induced mechanical hyperalgesia suggesting that these combina-
tions may be useful to reduce the dose of opioid required to control
G-CSF-induced pain. Others have observed similar synergy with
these drugs. For instance, thalidomide synergizes with morphine to
reduce spinal nerve injury-induced neuropathic pain in rats (Lee
et al., 2013). Pentoxifylline potentiated the anti-allodynia and anti-
hyperalgesic effects of morphine in chronic constriction injury in
rats (Mika et al., 2007) and pentoxifylline also attenuates morphine
tolerance in naïve and neuropathic mice (Mika et al., 2009).
Importantly, patients that received pentoxifylline presented longer
patient-controlled analgesia, faster return of bowel function and
consumed less morphine (Lu et al., 2004; Wordliczek et al., 2000).
Co-treatment with morphine and thalidomide or pentoxifylline
inhibited G-CSF-induced TNFα and IL-1β production indicating a
contributing mechanism to this synergy. Therefore, together with
our data, the literature suggests that combining morphine with
thalidomide or pentoxifylline is a promising therapeutic approach
to achieve better analgesic proﬁle and reduce morphine tolerance,
side effects and intake (Lee et al., 2013; Lu et al., 2004; Mika et al.,
2007, 2009; Wordliczek et al., 2000).
Indomethacin (cyclooxygenase inhibitor) inhibited G-CSF-
induced mechanical hyperalgesia, and combined treatment with
Fig. 8. Effect of analgesic treatments on G-CSF-induced peripheral blood neutrophil counts. Mice were treated with the indicated vehicle, IL-1ra (diluted in saline, 100
pg/paw 30 min before and 30 mg/kg i.p. 30 min before), etanercept (diluted in saline, 100 mg/paw 1 h before and 10 mg/kg i.p. 48 and 1 h before), morphine (diluted in saline,
6 mg/25 ml i.pl. 4 h after), thalidomide (diluted in DMSO 2% in saline, 45 mg/kg i.p. 30 min before), pentoxifylline (diluted in DMSO 2% in saline, 13.5 mg/kg i.p. 30 min before)
or indomethacin (diluted in Tris/HCl buffer, 5 mg/kg i.p. 40 min before) and received saline i.pl. or G-CSF (100 ng/paw). Total leukocytes (Panel A), mononuclear cell (Panel B)
and neutrophil (Panel C) counts were performed 24 h after the i.pl. injection of G-CSF. Results are presented as mean7S.E.M. of 6 mice per group per experiment, and are
representative of 2 separated experiments. *Po0.05 compared to the saline i.pl.þvehicle i.p. group; #Po0.05 compared to the G-CSFþsaline i.p. groups (One-way ANOVA
followed by Tukey's t-test).
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indomethacin and thalidomide or pentoxifylline at ineffective
doses as single treatment also reduced G-CSF-induced hyperalge-
sia. These data corroborate evidence that TNFα and IL-1β induce
peripheral mechanical hyperalgesia by triggering prostaglandin
production (Verri et al., 2006) and non-narcotic drugs reduce
G-CSF-induced pain in humans (Filgrastim Package Insert, 2010).
Indomethacin also increases G-CSF-induced differentiation of
human promyelocytic leukemia cells (HL60) towards neutrophils
(Bunce et al., 1994), suggesting it would eventually contribute to
increase neutrophil counts.
The mechanism by which G-CSF induces mechanical hyperalge-
sia also involves spinal activation of PI3K and MAP kinases p38
kinase, c-Jun N-terminal kinase (JNK), and extracellular signal-
regulated kinase (ERK) in a synergic/sequential way (Carvalho
et al., 2011). These mechanisms are also endogenously activated
by G-CSF in cancer pain (Schweizerhof et al., 2009). The activation
of these kinases leads to increases in proinﬂammatory cytokine
production, including TNFα and IL-1β, and may also modulate ion
channels, and sensitize nociceptors inducing hyperalgesia (Gao and
Ji, 2010; Ji and Strichartz, 2004). On the other hand, this kinase
cascade-dependent spinal hyperalgesic mechanism of G-CSF might
be a result of peripheral production of cytokines such as TNFα and
IL-1β as well as peripheral cytokines induce further cytokine
production in the dorsal root ganglia and spinal cord. For instance,
peripheral injection of TNFα and IL-1β, or their endogenous
production upon injury of peripheral nervous system or inﬂamma-
tory stimulus induces mechanical hyperalgesia with kinase activa-
tion in the spinal cord and dorsal root ganglia (Binshtok et al., 2008;
Eijkelkamp et al., 2010; Gaultier et al., 2008; Morell et al., 2013;
Willemen et al., 2010). In agreement, G-CSF-induced mechanical
hyperalgesia was also inhibited by local paw treatment with
etanercept and IL-1ra. Nociceptive neurons express G-CSF receptor
indicating a possible direct neuronal effect of G-CSF. In fact, there is
evidence that G-CSF sensitizes nociceptors (Schweizerhof et al.,
2009). Herein, G-CSF-induced mechanical hyperalgesia was depen-
dent on local production/action of TNF-α and IL-1β, which supports
the notion that G-CSF also induces peripheral nociceptor sensitiza-
tion dependent on further production of hyperalgesic molecules.
Because increasing neutrophil counts in peripheral blood is the
primary therapeutic use of G-CSF (Filgrastim Package Insert, 2010),
whether the analgesic approaches proposed in the present study
affect the neutrophil counts in peripheral blood should be deter-
mined. IL-1ra, but not etanercept, at a dose with the systemic
effect reduced the G-CSF-induced increase of neutrophil counts in
peripheral blood, indicating this G-CSF therapeutic effect depends
on systemic IL-1 action. A possible explanation for this pro-
nounced role of IL-1 in G-CSF therapy is that IL-1α and IL-1β do
not trigger a robust activation of neutrophils, but rather prolong
neutrophil survival (Futosi et al., 2013). On the other hand, TNFα is
more related to neutrophil activation, priming and apoptosis; thus,
inhibiting TNFα would increase the number of neutrophils (Futosi
et al., 2013). Nevertheless, IL-1ra and etanercept at doses with the
local effect did not change the output of neutrophils from bone
marrow indicating that G-CSF-induced local inﬂammatory reac-
tion is not of importance to its recruitment of neutrophil from the
bone marrow to peripheral blood.
IL-1ra, etanercept and morphine at locally acting doses, and
etanercept, thalidomide, pentoxifylline and indomethacin at sys-
temic doses are analgesic approaches of potential usefulness in
G-CSF-induced hyperalgesia because did not affect G-CSF-induced
increase of neutrophil counts in peripheral blood. Interestingly,
thalidomide and pentoxifylline reduced G-CSF-induced IL-1β produc-
tion without affecting the recruitment of bone marrow neutrophils,
which is in apparent contradiction to the inhibition of neutrophil
counts observed with systemic IL-1ra treatment. However, thalido-
mine and pentoxifylline partially inhibited G-CSF-induced paw skin
IL-1β production while systemic IL-1ra abolished G-CSF-induced
recruitment of bone marrow neutrophils. Thus, IL-1β seems to have
a more pronounced role in G-CSF-induced recruitment of bone
marrow neutrophils compared to its hyperalgesic effect, and the
G-CSF-induced hyperalgesia depends on IL-1β and TNFα while TNFα
does not have a role in G-CSF-induced bone marrow neutrophil
recruitment. Moreover, thalidomide and pentoxifylline have addi-
tional mechanisms of action. For instance, thalidomide interacts with
protein kinase C (PKC) to modulate chemoattraction (Meierhofer
et al., 1999), and inhibits adhesion molecules expression (Settles
et al., 2001), and inhibitor of kappa B (IκB) kinase (IKK) activation
(Keifer et al., 2001). Pentoxifylline is a competitive nonselective
phosphodiesterase inhibitor, which increases intracellular cyclic
adenosine monophosphate (cAMP) levels resulting in inhibition of
nuclear facto kappa B (NFκB) and nuclear factor of activated T-cells
(NFAT) activation (Essayan, 2001; Ribeiro de Jesus et al., 2008),
inhibits transforming growth factor-beta (TGFβ)/Smad signaling
(Ng et al., 2009) and antioxidant (Vircheva et al., 2010). These
mechanisms may contribute to their analgesic effect in addition to
reduce TNFα and IL-1β production.
5. Conclusion
The present study demonstrates that TNFα, IL-1β and IL-10
have key roles in G-CSF-induced mechanical hyperalgesia in mice.
TNFα and IL-1β mediate the pro-hyperalgesic effect of G-CSF and
IL-10 has an endogenous role to limit G-CSF hyperalgesia. Systemic
IL-1 seems to have a major role in G-CSF-induced recruitment of
neutrophils from the bone marrow to peripheral blood; thus,
targeting IL-1 will reduce the G-CSF therapeutic effect. Targeting
TNFα and IL-1β using biological therapies at locally acting doses,
and TNFα at systemic doses can inhibit G-CSF-induced mechanical
hyperalgesia without affecting the increased peripheral blood
neutrophil counts. In addition to biological therapies, targeting
TNFα and IL-1β with thalidomide and pentoxifylline is a concei-
vable therapeutic approache to control G-CSF-induced mechanical
hyperalgesia and to reduce the morphine usage. The inhibition of
cyclooxygenase represented by indomethacin is also a conceivable
analgesic approach, which can be used in combination with
thalidomide and pentoxifylline.
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